Nuo Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
August 19, 2019 at 04:34 pm EDT
Share
Nuo Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced total revenue was USD 44,165 compared to USD 138,309 a year ago. Operating loss was USD 392,445 compared to USD 582,664 a year ago. Net loss was USD 480,288 compared to USD 590,163 a year ago. Basic loss per share was USD 0.02 compared to USD 0.03 a year ago. For the half year, total revenue was USD 83,394 compared to USD 298,252 a year ago. Operating loss was USD 1.004 million compared to USD 1.250 million a year ago. Net loss was USD 1.160 million compared to USD 1.260 million a year ago. Basic loss per share was USD 0.05 compared to USD 0.06 a year ago.
Nuo Therapeutics, Inc. is a regenerative therapies company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. Its flagship product, Aurix, is a biodynamic hematogel that uses a patientâs own platelets and plasma as a catalyst for healing. The Companyâs commercial offering consists of point of care technology for the safe and effective separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix (the Aurix System), which produces a platelet rich plasma (PRP) gel at the point of care using the patientâs own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
NUO THERAPEUTICS, INC. 
